Efficacy and Safety of Adalimumab in Patients with Behcet Uveitis: A Systematic Review and Meta-Analysis


ŞENER H., EVEREKLİOĞLU C., HOROZOĞLU F., Sener A. B.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.32, sa.1, ss.89-97, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1080/09273948.2022.2157288
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.89-97
  • Anahtar Kelimeler: Adalimumab, Behcet, iridocyclitis, TNF-alpha, uveitis, panuveitis, NONINFECTIOUS UVEITIS, TNF-ALPHA, OCULAR COMPLICATIONS, DISEASE, STANDARDIZATION, INTERMEDIATE, INFLAMMATION, MULTICENTER, PREVALENCE, FREQUENCY
  • Kayseri Üniversitesi Adresli: Hayır

Özet

PurposeTo examine the long-term efficacy and safety of adalimumab (ADA) in patients with Behcet uveitis (BU).MethodsA systematic review and meta-analysis of observational studies was performed. Pooled results are presented as mean difference or standardized mean difference (std diff) and 95% confidence intervals (CI). Visual acuity (VA), intraocular inflammation grade, central macular thickness, corticosteroid (CS) sparing effect and adverse events were evaluated.ResultsTen studies were included finally for quantitative and qualitative synthesis. ADA therapy resulted in 0.124 (95%CI: 0.084, 0.165) logMAR improvement in VA. In addition, ADA therapy resulted in decreased grade of intraocular inflammation [std diff, -1.187 (95%CI: -1.508, -0.866)] and macular thickness [std diff, -0.564 (95%CI: -0.843, -0.286)] and caused a decrease in CS dosage [std diff, -1.809 (95%CI: -2.420, -1.198)]. The pooled rate of overall adverse events for ADA in 301 patients was 8.5% (95%CI: 0.039, 0.177).ConclusionADA is an efficient therapy that improves VA and controls intraocular inflammation, macular edema and retinal vasculitis. As the disease exposure time increased, improvement in VA was less. The safety and CS-sparing effect of ADA were demonstrated with few adverse effects. The results provided evidence that ADA can be used safely and efficiently as the first-line drug in patients with BU.